<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="CureusCureus2168-8184Cureus2168-8184CureusPalo Alto (CA) pmcid: 7496561 doi: 10.7759/cureus.10480 : Internal Medicine:" exact="Infectious" post="Disease: Epidemiology/Public Health Therapeutic Options for COVID-19: A Review"/>
 <result pre="provided the original author and source are credited.https://www.cureus.com/articles/39625-therapeutic-options-for-covid-19-a-review Abstract An" exact="acute" post="respiratory diseaseÂ caused by a novel coronavirus [severe acute"/>
 <result pre="the original author and source are credited.https://www.cureus.com/articles/39625-therapeutic-options-for-covid-19-a-review Abstract An acute" exact="respiratory" post="diseaseÂ caused by a novel coronavirus [severe acute respiratory"/>
 <result pre="An acute respiratory diseaseÂ caused by a novel coronavirus [severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV],"/>
 <result pre="acute respiratory diseaseÂ caused by a novel coronavirus [severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the"/>
 <result pre="respiratory diseaseÂ caused by a novel coronavirus [severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus" exact="disease" post="2019 (COVID-19) was first detected in Wuhan, China. Since"/>
 <result pre="identify a viable therapeutic option to mitigate the damage the" exact="disease" post="causes. In spite of various governments implementing aggressive global"/>
 <result pre="virus is going to be challenging owing to the possible" exact="viral" post="genetic recombination. Extensive research is still needed to safely"/>
 <result pre="of diseases in the past, including Ebola, cholera,Â Middle East" exact="respiratory" post="syndrome (MERS), the novel coronavirus pandemic has undoubtedly proven"/>
 <result pre="diseases in the past, including Ebola, cholera,Â Middle East respiratory" exact="syndrome" post="(MERS), the novel coronavirus pandemic has undoubtedly proven to"/>
 <result pre="the severity of this crisis. The specific symptomatology of coronavirus" exact="disease" post="2019 (COVID-19) has been challenging to define with the"/>
 <result pre="have also been reported [1]. The most common patterns on" exact="chest" post="CT imaging in these patients includeÂ ground-glass opacity (56.4%)"/>
 <result pre="CT imaging in these patients includeÂ ground-glass opacity (56.4%) and" exact="bilateral" post="patchy shadowing (51.8%). Laboratory findings includeÂ lymphocytopenia in 83.2%"/>
 <result pre="shadowing (51.8%). Laboratory findings includeÂ lymphocytopenia in 83.2% of patients," exact="thrombocytopenia" post="in 36.2%, and leukopenia in 33.7% people [2]. Severe"/>
 <result pre="includeÂ lymphocytopenia in 83.2% of patients, thrombocytopenia in 36.2%, and" exact="leukopenia" post="in 33.7% people [2]. Severe acute respiratory syndrome coronavirus"/>
 <result pre="patients, thrombocytopenia in 36.2%, and leukopenia in 33.7% people [2]." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a betacoronavirus"/>
 <result pre="thrombocytopenia in 36.2%, and leukopenia in 33.7% people [2]. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is a betacoronavirus belonging"/>
 <result pre="in 36.2%, and leukopenia in 33.7% people [2]. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is a betacoronavirus belonging to"/>
 <result pre="36.2%, and leukopenia in 33.7% people [2]. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is a betacoronavirus belonging to the"/>
 <result pre="betacoronavirus belonging to the Orthocoronavirinae subfamily, which also includes severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) that caused the severe acute"/>
 <result pre="belonging to the Orthocoronavirinae subfamily, which also includes severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) that caused the severe acute respiratory"/>
 <result pre="to the Orthocoronavirinae subfamily, which also includes severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) that caused the severe acute respiratory syndrome"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) that caused the severe" exact="acute" post="respiratory syndrome (SARS) outbreak in 2002 and the Middle"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV) that caused the severe acute" exact="respiratory" post="syndrome (SARS) outbreak in 2002 and the Middle East"/>
 <result pre="respiratory syndrome coronavirus (SARS-CoV) that caused the severe acute respiratory" exact="syndrome" post="(SARS) outbreak in 2002 and the Middle East respiratory"/>
 <result pre="respiratory syndrome (SARS) outbreak in 2002 and the Middle East" exact="respiratory" post="syndrome coronavirus (MERS CoV), which caused the MERS outbreak"/>
 <result pre="syndrome (SARS) outbreak in 2002 and the Middle East respiratory" exact="syndrome" post="coronavirus (MERS CoV), which caused the MERS outbreak in"/>
 <result pre="the structural protein (spike protein) play an important role in" exact="viral" post="pathogenesis and hence they are being recognized as potential"/>
 <result pre="can help to analyze the effects of these drugs on" exact="viral" post="replication. Several drugs have been identified using this method,"/>
 <result pre="interfering RNA (siRNA) molecules or enzymes that will target specific" exact="viral" post="enzymes, inhibition of host cell protease, or host viral"/>
 <result pre="specific viral enzymes, inhibition of host cell protease, or host" exact="viral" post="endocytosis. Although this seems an effective option because of"/>
 <result pre="option because of these drugs' specific anti-coronavirus properties, there is" exact="limited" post="data regarding the safety profile as well as the"/>
 <result pre="AlphaCoVs (HCoV-229E and HCoV-NL63) can cause the common cold and" exact="upper" post="respiratory infections in immunocompetent individuals while lower respiratory infections"/>
 <result pre="(HCoV-229E and HCoV-NL63) can cause the common cold and upper" exact="respiratory" post="infections in immunocompetent individuals while lower respiratory infections can"/>
 <result pre="and HCoV-NL63) can cause the common cold and upper respiratory" exact="infections" post="in immunocompetent individuals while lower respiratory infections can occur"/>
 <result pre="common cold and upper respiratory infections in immunocompetent individuals while" exact="lower" post="respiratory infections can occur inÂ immunocompromised people. Other human"/>
 <result pre="cold and upper respiratory infections in immunocompetent individuals while lower" exact="respiratory" post="infections can occur inÂ immunocompromised people. Other human CoVs,"/>
 <result pre="and upper respiratory infections in immunocompetent individuals while lower respiratory" exact="infections" post="can occur inÂ immunocompromised people. Other human CoVs, BetaCoVs"/>
 <result pre="lineage (SARS-CoV, SARS-CoV-2, and MERS-CoV respectively) cause epidemics involving the" exact="respiratory" post="and extra-respiratory systems [6]. GeneticÂ characterization has exhibited that"/>
 <result pre="this large family group can cause neurologic, hepatic, respiratory, and" exact="intestinal diseases" post="in multiple animal species, which include bats, cats, camels,"/>
 <result pre="which include bats, cats, camels, cattle, and cases of COVID" exact="infection" post="have also been detected in feline families in the"/>
 <result pre="SARS-CoV2 originated from bats, the role of pangolins acting as" exact="intermediate" post="hosts is also being considered. A study has revealed"/>
 <result pre="the likelihood of human to human transmission was considered. Although" exact="symptomatic" post="individuals are the most important source of COVID-19 spread,"/>
 <result pre="the transmission of this virus is believed to be through" exact="respiratory" post="droplets generated during coughing and sneezing, similar to other"/>
 <result pre="respiratory droplets generated during coughing and sneezing, similar to other" exact="viral" post="respiratory conditions. Another possible mode of transmission is through"/>
 <result pre="droplets generated during coughing and sneezing, similar to other viral" exact="respiratory" post="conditions. Another possible mode of transmission is through exposure"/>
 <result pre="found in the lungsÂ (type 2 pneumocytes, tracheal, and bronchial" exact="epithelial" post="cells, macrophages). These ACE2 receptors serve as entry points"/>
 <result pre="(HR2), plays a role in virus-cell membrane fusion. Thereafter, the" exact="viral" post="genomic RNA that is released in the cytoplasm translates"/>
 <result pre="and Golgi bodies congregate and result in the formation of" exact="viral" post="particle buds, which then attach to the plasma membrane"/>
 <result pre="also known as a &quot;cytokine storm&quot;. Cytokines such as the" exact="tumor" post="necrosis factor Î± (TNF-Î±), interleukin-1-beta (IL-1Î²), interleukin-8 (IL-8), interleukin-12"/>
 <result pre="interferon-gamma inducible protein (IP10), macrophage inflammatory protein 1A (MIP-1a), and" exact="monocyte" post="chemoattractant protein 1 (MCP1) are released, resulting in the"/>
 <result pre="(MCP1) are released, resulting in the pathogenic cascade of the" exact="disease" post="that leads to extensive tissue damage with dysfunctional coagulation."/>
 <result pre="is producedÂ mostly by activated leukocytes, seems to play the" exact="primary" post="role in this cascade. IL-6Â promotes the differentiation of"/>
 <result pre="lymphocytes and stimulates the production of acute-phase proteins. Cytokine release" exact="syndrome" post="(CRS) is an acute systemic inflammatory syndrome that is"/>
 <result pre="production of acute-phase proteins. Cytokine release syndrome (CRS) is an" exact="acute" post="systemic inflammatory syndrome that is mediated by IL-6. It"/>
 <result pre="of acute-phase proteins. Cytokine release syndrome (CRS) is an acute" exact="systemic" post="inflammatory syndrome that is mediated by IL-6. It is"/>
 <result pre="proteins. Cytokine release syndrome (CRS) is an acute systemic inflammatory" exact="syndrome" post="that is mediated by IL-6. It is characterized by"/>
 <result pre="its active mature form. IL-1Î² plays a major role in" exact="lung inflammation" post="and fibrosis seen in patients with COVID-19 [6]. With"/>
 <result pre="seen in patients with COVID-19 [6]. With this knowledge of" exact="viral" post="replication and pathogenesis, we can explore various possible therapeutic"/>
 <result pre="components of SARS-CoV-2* *[11] RNA: ribonucleic acid;Â SARS-CoV 2: severe" exact="acute" post="respiratory syndrome coronavirus 2 Pharmacological targets Coronavirus replicates by"/>
 <result pre="of SARS-CoV-2* *[11] RNA: ribonucleic acid;Â SARS-CoV 2: severe acute" exact="respiratory" post="syndrome coronavirus 2 Pharmacological targets Coronavirus replicates by recruiting"/>
 <result pre="SARS-CoV-2* *[11] RNA: ribonucleic acid;Â SARS-CoV 2: severe acute respiratory" exact="syndrome" post="coronavirus 2 Pharmacological targets Coronavirus replicates by recruiting nonstructural"/>
 <result pre="[12]. These four non-structural proteins are key enzymes within the" exact="viral" post="life cycle. In addition, the spike glycoprotein is indispensable"/>
 <result pre="the spike glycoprotein is indispensable for virus-cell receptor interactions during" exact="viral" post="entry. These viral proteins were therefore considered as important"/>
 <result pre="is indispensable for virus-cell receptor interactions during viral entry. These" exact="viral" post="proteins were therefore considered as important targets to develop"/>
 <result pre="the potential for repurposing existing antiviral agents to treat SARS-CoV-2" exact="infection" post="with their site of action as shown in Figure"/>
 <result pre="for antiviral agents since they play an important role in" exact="viral" post="replication and controlling the host cell. Decoded 3CLpro of"/>
 <result pre="by binding to oligosaccharides found on the surface of numerous" exact="viral" post="glycoproteins including SARS-CoV spike glycoprotein and HIV glycoprotein 120."/>
 <result pre="Figure 2 Pharmacological targets for SARS-CoV-2* *[14] SARS-CoV 2: severe" exact="acute" post="respiratory syndrome coronavirus 2;Â ACE2: angiotensin-converting enzyme 2;Â AAK1:"/>
 <result pre="2 Pharmacological targets for SARS-CoV-2* *[14] SARS-CoV 2: severe acute" exact="respiratory" post="syndrome coronavirus 2;Â ACE2: angiotensin-converting enzyme 2;Â AAK1: adaptor-associated"/>
 <result pre="Pharmacological targets for SARS-CoV-2* *[14] SARS-CoV 2: severe acute respiratory" exact="syndrome" post="coronavirus 2;Â ACE2: angiotensin-converting enzyme 2;Â AAK1: adaptor-associated protein"/>
 <result pre="2017, Gilead Sciences developed RDV for the treatment of Ebola" exact="virus infection." post="It is a broad-spectrum drug having antiviral activities against"/>
 <result pre="The host metabolizes RDV into the active triphosphate form.Â The" exact="primary" post="mechanism of inhibition is the incorporation of RDV-TP into"/>
 <result pre="This causes delayed RNA chain termination during the process of" exact="viral" post="replication [15].Â Principle behind use: RDV has been shown"/>
 <result pre="shown to have activity against varying coronaviruses in the airway" exact="epithelial" post="cells in humans [12]. Preliminary results of theÂ Adaptive"/>
 <result pre="or laboratory-confirmed COVID-19, which was later expanded to include all" exact="adult" post="and pediatric patients hospitalized with suspected or laboratory-confirmed COVID-19,"/>
 <result pre="in suspected COVID-19 patients whose laboratory results are pending.Â -" exact="Adult" post="and pediatric patients (older than 28 days of age)"/>
 <result pre="creatinine determined before dosing and daily while receiving RDV. -" exact="Hepatic" post="laboratory testing should be performed in all patients before"/>
 <result pre="only. For pediatric patients weighing 40 kg and higher, the" exact="adult" post="dosage regimen of a single loading dose of 200"/>
 <result pre="administration outside the hospital in the early stages of the" exact="disease" post="[17]. Adverse effects and challenges: as for safety, according"/>
 <result pre="as for safety, according to Gilead Sciences, infusion-related and anaphylactic" exact="hypersensitivity" post="reactions were seen following RDV administration, which could be"/>
 <result pre="the infusion rates. RDV is contraindicated in patients with known" exact="hypersensitivity" post="reactions. Elevated transaminases were observed in patients with COVID-19"/>
 <result pre="rates. RDV is contraindicated in patients with known hypersensitivity reactions." exact="Elevated" post="transaminases were observed in patients with COVID-19 and, therefore,"/>
 <result pre="â‰¥5x ULN or ALT elevation accompanied by signs or symptoms" exact="of liver" post="inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR"/>
 <result pre="ULN or ALT elevation accompanied by signs or symptoms of" exact="liver inflammation" post="or increasing conjugated bilirubin, alkaline phosphatase, or INR (international"/>
 <result pre="reduced if co-administered with chloroquine phosphate or hydroxychloroquine sulfate [16]." exact="Multiple" post="clinical trials are ongoing on the use of RDV"/>
 <result pre="being used as a therapeutic option in various conditions like" exact="myasthenia gravis," post="Guillain-BarrÃ© syndrome, chronic inflammatory demyelinating polyneuropathy, fulminant Wilson's disease,"/>
 <result pre="therapeutic option in various conditions like myasthenia gravis, Guillain-BarrÃ© syndrome," exact="chronic" post="inflammatory demyelinating polyneuropathy, fulminant Wilson's disease, hypergammaglobulinemia manifested with"/>
 <result pre="in various conditions like myasthenia gravis, Guillain-BarrÃ© syndrome, chronic inflammatory" exact="demyelinating" post="polyneuropathy, fulminant Wilson's disease, hypergammaglobulinemia manifested with hyperviscosity, thrombotic"/>
 <result pre="like myasthenia gravis, Guillain-BarrÃ© syndrome, chronic inflammatory demyelinating polyneuropathy, fulminant" exact="Wilson's disease," post="hypergammaglobulinemia manifested with hyperviscosity, thrombotic thrombocytopenic purpura, complement-mediated thrombotic"/>
 <result pre="gravis, Guillain-BarrÃ© syndrome, chronic inflammatory demyelinating polyneuropathy, fulminant Wilson's disease," exact="hypergammaglobulinemia" post="manifested with hyperviscosity, thrombotic thrombocytopenic purpura, complement-mediated thrombotic microangiopathy,"/>
 <result pre="inflammatory demyelinating polyneuropathy, fulminant Wilson's disease, hypergammaglobulinemia manifested with hyperviscosity," exact="thrombotic thrombocytopenic purpura," post="complement-mediated thrombotic microangiopathy, and Goodpasture syndrome [18]. MOA: therapeutic"/>
 <result pre="demyelinating polyneuropathy, fulminant Wilson's disease, hypergammaglobulinemia manifested with hyperviscosity, thrombotic" exact="thrombocytopenic purpura," post="complement-mediated thrombotic microangiopathy, and Goodpasture syndrome [18]. MOA: therapeutic"/>
 <result pre="manifested with hyperviscosity, thrombotic thrombocytopenic purpura, complement-mediated thrombotic microangiopathy, and" exact="Goodpasture syndrome" post="[18]. MOA: therapeutic plasma exchange is â€œa therapeutic procedure"/>
 <result pre="with hyperviscosity, thrombotic thrombocytopenic purpura, complement-mediated thrombotic microangiopathy, and Goodpasture" exact="syndrome" post="[18]. MOA: therapeutic plasma exchange is â€œa therapeutic procedure"/>
 <result pre="[19]. The efficacy of convalescent blood products in cases of" exact="viral" post="infections was first noted during Spanish influenza. Thereafter, the"/>
 <result pre="The efficacy of convalescent blood products in cases of viral" exact="infections" post="was first noted during Spanish influenza. Thereafter, the possibility"/>
 <result pre="plasma for prevention and/or treatment gathered interest during the West" exact="African" post="Ebola outbreak. Various other infections caused by West Nile"/>
 <result pre="gathered interest during the West African Ebola outbreak. Various other" exact="infections" post="caused by West Nile Virus, MERS-CoV, and SARS-CoV-1 have"/>
 <result pre="IL-7, IL-10, granulocyte colony-stimulating factor (G-CSF), MCP1, MIP-1a, and TNF-Î±," exact="secondary" post="to the upregulation of the inflammatory process in COVID-19"/>
 <result pre="COVID-19 [21]. As suggested by Lin et al. [22], the" exact="viral" post="attack occurs in two stages. In the first stage,"/>
 <result pre="lymphocyte count continues to drop over the course of the" exact="disease" post="along with a rise in inflammatory cytokines. Therefore, an"/>
 <result pre="eligibility for treatment with plasma exchange:Â 1. Laboratory-confirmed COVID-19 2." exact="Severe" post="or immediately life-threatening COVID-19; for example, severe disease is"/>
 <result pre="COVID-19 2. Severe or immediately life-threatening COVID-19; for example, severe" exact="disease" post="is defined as the presence of one or more"/>
 <result pre="the following: Â - Shortness of breath (dyspnea), Â -" exact="Respiratory" post="frequency of â‰¥30/min, Â - Blood oxygen saturation of"/>
 <result pre="breath (dyspnea), Â - Respiratory frequency of â‰¥30/min, Â -" exact="Blood" post="oxygen saturation of â‰¤93%, Â - Partial pressure of"/>
 <result pre="â‰¥30/min, Â - Blood oxygen saturation of â‰¤93%, Â -" exact="Partial" post="pressure of arterial oxygen to fraction of inspired oxygen"/>
 <result pre="Lung infiltrates of &amp;gt;50% within 24 to 48 hours. Life-threatening" exact="disease" post="is defined as the presence of one or more"/>
 <result pre="presence of one or more of the following: Â -" exact="Respiratory" post="failure, Â - Septic shock, Â - Multiple organ"/>
 <result pre="Â - Respiratory failure, Â - Septic shock, Â -" exact="Multiple" post="organ dysfunction or failure. 3. Informed consent provided by"/>
 <result pre="include allergic transfusion reactions, transfusion-associated circulatory overload (TACO), and transfusion-related" exact="acute" post="lung injury (TRALI). TRALIÂ is especially important in critically"/>
 <result pre="ill patients due to COVID-19. These patients may have underlying" exact="acute" post="respiratory distress syndrome (ARDS), which could be worsened by"/>
 <result pre="patients due to COVID-19. These patients may have underlying acute" exact="respiratory" post="distress syndrome (ARDS), which could be worsened by TRALI."/>
 <result pre="to COVID-19. These patients may have underlying acute respiratory distress" exact="syndrome" post="(ARDS), which could be worsened by TRALI. Volume overload"/>
 <result pre="by TRALI. Volume overload (TACO)Â has the potential to precipitate" exact="pulmonary" post="edema, especially in older adults, small children, and those"/>
 <result pre="especially in older adults, small children, and those with preexisting" exact="cardiac disease." post="Anaphylactic reactions may occur in patients with Immunoglobulin A"/>
 <result pre="preexisting cardiac disease. Anaphylactic reactions may occur in patients with" exact="Immunoglobulin A" post="(IgA) deficiency and antibodies to IgA [19]. A potential"/>
 <result pre="Anaphylactic reactions may occur in patients with Immunoglobulin A (IgA)" exact="deficiency" post="and antibodies to IgA [19]. A potential challenge that"/>
 <result pre="frequent recipients of plasma exchange [20]. Chloroquine Current applications: the" exact="primary" post="indication for chloroquine and hydroxychloroquine is to prevent or"/>
 <result pre="indication for chloroquine and hydroxychloroquine is to prevent or treat" exact="malaria" post="and also in the treatment of several infections like"/>
 <result pre="or treat malaria and also in the treatment of several" exact="infections" post="like HIV, Q fever, WhippleÂ disease, and fungal infections."/>
 <result pre="and also in the treatment of several infections like HIV," exact="Q fever," post="WhippleÂ disease, and fungal infections. Other indicationsÂ of these"/>
 <result pre="indicationsÂ of these drugs include immunological and rheumatologic disorders like" exact="systemic" post="lupus erythematosus (SLE), antiphospholipid antibody syndrome, rheumatoid arthritis, and"/>
 <result pre="of these drugs include immunological and rheumatologic disorders like systemic" exact="lupus erythematosus" post="(SLE), antiphospholipid antibody syndrome, rheumatoid arthritis, and SjÃ¶gren's syndrome.Â"/>
 <result pre="include immunological and rheumatologic disorders like systemic lupus erythematosus (SLE)," exact="antiphospholipid antibody syndrome," post="rheumatoid arthritis, and SjÃ¶gren's syndrome.Â Chloroquine and hydroxychloroquine have"/>
 <result pre="rheumatologic disorders like systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome," exact="rheumatoid arthritis," post="and SjÃ¶gren's syndrome.Â Chloroquine and hydroxychloroquine have been found"/>
 <result pre="inhibition of autophagosome-lysosome fusion and inactivation of enzymes required for" exact="viral" post="replication [25]. Chloroquine demonstrates broad-spectrum antiviral activity against human"/>
 <result pre="protein kinase (MAPK) signaling is an important step in the" exact="viral" post="replication cycle. Chloroquine prevents phosphorylation of p38 MAPK in"/>
 <result pre="and B virus, Zika virus, and DNA viruses include the" exact="hepatitis" post="B virus and herpes simplex virus. Coronavirus being an"/>
 <result pre="virus, and DNA viruses include the hepatitis B virus and" exact="herpes" post="simplex virus. Coronavirus being an RNA virus, chloroquine has"/>
 <result pre="chloroquine has demonstrated in vitro inhibition of HCoV-229E replication in" exact="epithelial" post="lung cultures. InÂ another study, it was concluded that"/>
 <result pre="epithelial lung cultures. InÂ another study, it was concluded that" exact="infections" post="in recently born mice with the HCoV-O43 coronavirus could"/>
 <result pre="the effective dose of chloroquine for the treatment of COVID-19" exact="infection" post="has been found to be 500 mg twice daily"/>
 <result pre="required. These doses are higher than recommended in cases of" exact="malaria" post="prophylaxis and clinical trials are needed to establish safety"/>
 <result pre="critically ill patients with COVID-19 [30]. Hydroxychloroquine can cause serious" exact="cutaneous" post="adverse reactions, fulminant hepatic failure, and ventricular arrhythmias likeÂ"/>
 <result pre="avoided. Administration of hydroxychloroquine and chloroquine requires frequent monitoring of" exact="complete" post="blood count, which includes red blood cells (RBC), white"/>
 <result pre="[liver function tests (LFTs)] and renal functions. Other contraindications include" exact="hypersensitivity" post="reactions, retinopathy, porphyria, epilepsy, pre-existing maculopathy, glucose-6-phosphate dehydrogenase (G6PD)"/>
 <result pre="retinopathy, porphyria, epilepsy, pre-existing maculopathy, glucose-6-phosphate dehydrogenase (G6PD) deficiency,Â recent" exact="myocardial infarction" post="(MI), and QTc of &amp;gt;500 msec [28]. Lopinavir Current"/>
 <result pre="LPV [12]. This combination has been found to effectively reduce" exact="viral" post="load in HIV patients leading to an interest in"/>
 <result pre="proteases are vital enzymes that play an important role in" exact="viral" post="replication, maturation, and assembly process. Inhibition of these protease"/>
 <result pre="of the replicase polyprotein, which in turn is vital for" exact="viral" post="replication and maturation [32]. LPV/r has shown promising results"/>
 <result pre="chimeric antigen receptor (CAR) T cell-induced CRS,Â giant cell arteritis," exact="rheumatoid arthritis" post="(RA), and polyarticular or systemic juvenile arthritis [35,36].Â MOA:"/>
 <result pre="antigen receptor (CAR) T cell-induced CRS,Â giant cell arteritis, rheumatoid" exact="arthritis" post="(RA), and polyarticular or systemic juvenile arthritis [35,36].Â MOA:"/>
 <result pre="CRS,Â giant cell arteritis, rheumatoid arthritis (RA), and polyarticular or" exact="systemic" post="juvenile arthritis [35,36].Â MOA: as mentioned above, excess stimulation"/>
 <result pre="giant cell arteritis, rheumatoid arthritis (RA), and polyarticular or systemic" exact="juvenile" post="arthritis [35,36].Â MOA: as mentioned above, excess stimulation of"/>
 <result pre="cell arteritis, rheumatoid arthritis (RA), and polyarticular or systemic juvenile" exact="arthritis" post="[35,36].Â MOA: as mentioned above, excess stimulation of the"/>
 <result pre="IP10, and MCP1. This leads to a condition of severe" exact="systemic" post="inflammatory response also known as CRS [37]. In these"/>
 <result pre="CRS [37]. In these patients, in spite of having diminishing" exact="viral" post="loads, the reason for their deteriorating health is the"/>
 <result pre="towards the use of tocilizumab is advised since there is" exact="limited" post="data on its efficacy and potential toxicity. Its use"/>
 <result pre="its efficacy and potential toxicity. Its use in patients with" exact="tuberculosis" post="(TB) or any active infection is contraindicated. Elevated IL-6"/>
 <result pre="Its use in patients with tuberculosis (TB) or any active" exact="infection" post="is contraindicated. Elevated IL-6 levels have been seen as"/>
 <result pre="patients with tuberculosis (TB) or any active infection is contraindicated." exact="Elevated" post="IL-6 levels have been seen as an important inclusion"/>
 <result pre="in the above-mentioned studies, patients with RA who are on" exact="chronic" post="tocilizumab therapy were found to be at an increased"/>
 <result pre="platelets, neutrophils, and liver enzymes. Other common side effects are" exact="upper" post="respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and"/>
 <result pre="neutrophils, and liver enzymes. Other common side effects are upper" exact="respiratory" post="tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection"/>
 <result pre="a role in inhibiting cytokine release that can lead to" exact="cancer" post="cell growth. Baricitinib, a JAK inhibitor, is used in"/>
 <result pre="used in the treatment of some types of malignancies and" exact="autoimmune diseases" post="such as RA due to its immunomodulatory effect [40]."/>
 <result pre="is postulated that baricitinib could prevent the intracellular movement of" exact="viral" post="cells and the development of viral particles due to"/>
 <result pre="the intracellular movement of viral cells and the development of" exact="viral" post="particles due to its affinity for binding to associated"/>
 <result pre="intelligence (AI)-algorithmsÂ to be useful for the treatment of COVID-19" exact="infection" post="via proposed anti-cytokine effects and as an inhibitor of"/>
 <result pre="proposed anti-cytokine effects and as an inhibitor of host cell" exact="viral" post="propagation. As mentioned previously, CRS has been linked to"/>
 <result pre="has been found to inhibit IL-6-induced MCP1 production from human" exact="peripheral" post="blood mononuclear cells [41]. Adverse effects and challenges: lymphopenia"/>
 <result pre="human peripheral blood mononuclear cells [41]. Adverse effects and challenges:" exact="lymphopenia" post="and anemia have been identified as potential adverse effects"/>
 <result pre="blood mononuclear cells [41]. Adverse effects and challenges: lymphopenia and" exact="anemia" post="have been identified as potential adverse effects in multiple"/>
 <result pre="critically ill. Some studies have reported an increased incidence of" exact="respiratory" post="tract infections as high as 16.3% and an incidence"/>
 <result pre="Some studies have reported an increased incidence of respiratory tract" exact="infections" post="as high as 16.3% and an incidence of other"/>
 <result pre="infections as high as 16.3% and an incidence of other" exact="infectious diseases" post="as high as 29-42%. Co-infection is a significantÂ threat"/>
 <result pre="baricitinib. There is an increased risk of reactivation of latent" exact="infections" post="like TB, hepatitis B, Varicella-zoster, herpes simplex, and Epstein"/>
 <result pre="an increased risk of reactivation of latent infections like TB," exact="hepatitis" post="B, Varicella-zoster, herpes simplex, and Epstein Barr virus strains"/>
 <result pre="of reactivation of latent infections like TB, hepatitis B, Varicella-zoster," exact="herpes" post="simplex, and Epstein Barr virus strains [42]. As observed"/>
 <result pre="clearance of viruses, thereby resulting in an increased risk for" exact="secondary" post="infections [43]. This risk is further increased in elderly"/>
 <result pre="of viruses, thereby resulting in an increased risk for secondary" exact="infections" post="[43]. This risk is further increased in elderly patients"/>
 <result pre="[43]. Ribavirin Ribavirin is a guanosine analog that interferes with" exact="viral" post="RNA synthesis by inhibiting viral RdRp as well as"/>
 <result pre="guanosine analog that interferes with viral RNA synthesis by inhibiting" exact="viral" post="RdRp as well as messenger RNA (mRNA) capping [44]."/>
 <result pre="of MERS symptoms was seen when ribavirin was combined with" exact="type I" post="Interferons [44]. In a recent study,Â it was also"/>
 <result pre="ACE2 receptors are at a higher risk for severe COVID-19" exact="infection" post="[46]. Therefore, the balance of potential benefits and harms"/>
 <result pre="continuing ACEI or angiotensin receptor blockersÂ (ARB)Â therapy during an" exact="acute" post="infection depends on the reason for prescribing. Although these"/>
 <result pre="ACEI or angiotensin receptor blockersÂ (ARB)Â therapy during an acute" exact="infection" post="depends on the reason for prescribing. Although these drugs"/>
 <result pre="vast number of ongoing trials,Â trials in this chart are" exact="limited" post="to those withÂ &amp;gt;500 participants NCT ID: National Clinical"/>
 <result pre="ID: National Clinical Trial Identifier; ACE: angiotensin-converting enzyme;Â SARS-CoV-2:Â severe" exact="acute" post="respiratory syndrome coronavirus 2;Â COVID-19:Â coronavirus disease 2019 Intervention"/>
 <result pre="National Clinical Trial Identifier; ACE: angiotensin-converting enzyme;Â SARS-CoV-2:Â severe acute" exact="respiratory" post="syndrome coronavirus 2;Â COVID-19:Â coronavirus disease 2019 Intervention NCT"/>
 <result pre="Clinical Trial Identifier; ACE: angiotensin-converting enzyme;Â SARS-CoV-2:Â severe acute respiratory" exact="syndrome" post="coronavirus 2;Â COVID-19:Â coronavirus disease 2019 Intervention NCT ID"/>
 <result pre="enzyme;Â SARS-CoV-2:Â severe acute respiratory syndrome coronavirus 2;Â COVID-19:Â coronavirus" exact="disease" post="2019 Intervention NCT ID No. of participants Duration Phase"/>
 <result pre="vast number of ongoing trials,Â trials in this chart are" exact="limited" post="to those withÂ &amp;gt;1000 participants NCT ID: National Clinical"/>
 <result pre="&amp;gt;1000 participants NCT ID: National Clinical Trial Identifier;Â SARS-CoV-2:Â severe" exact="acute" post="respiratory syndrome coronavirus 2 Intervention NCT ID No. of"/>
 <result pre="participants NCT ID: National Clinical Trial Identifier;Â SARS-CoV-2:Â severe acute" exact="respiratory" post="syndrome coronavirus 2 Intervention NCT ID No. of participants*"/>
 <result pre="NCT ID: National Clinical Trial Identifier;Â SARS-CoV-2:Â severe acute respiratory" exact="syndrome" post="coronavirus 2 Intervention NCT ID No. of participants* Duration"/>
 <result pre="May 2020â€&quot;March 2021 Phase 2 National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) Drug: hydroxychloroquine; drug: placebo oral tablet NCT04318444"/>
 <result pre="2020â€&quot;March 2021 Phase 2 National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) Drug: hydroxychloroquine; drug: placebo oral tablet NCT04318444 1600"/>
 <result pre="May 2020â€&quot;August 2023 Phase 3 National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) Emerging options There are many emerging options"/>
 <result pre="2020â€&quot;August 2023 Phase 3 National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) Emerging options There are many emerging options being"/>
 <result pre="destroy surrounding tissues, facilitating microthrombosis leading to permanent damage to" exact="pulmonary" post="and other systems. The coagulation abnormality seen in infected"/>
 <result pre="5% had elevated prothrombin time (PT), 6% had elevated activated" exact="partial" post="thromboplastin time (aPTT), 36% had elevated D-dimer, with increased"/>
 <result pre="be possibly superior to LPV/ritonavir in treating COVID-19 because the" exact="viral" post="load was undetectable after administration of Arbidol in patients"/>
 <result pre="2020 Phase 3 Estudios ClÃ­nicos Latino AmÃ©rica Drug: colchicine plus" exact="symptomatic" post="treatment (paracetamol); drug: symptomatic treatment (paracetamol or best symptomatic"/>
 <result pre="ClÃ­nicos Latino AmÃ©rica Drug: colchicine plus symptomatic treatment (paracetamol); drug:" exact="symptomatic" post="treatment (paracetamol or best symptomatic treatment based on doctor"/>
 <result pre="plus symptomatic treatment (paracetamol); drug: symptomatic treatment (paracetamol or best" exact="symptomatic" post="treatment based on doctor recommendations) NCT04416334 1028 May 2020â€&quot;December"/>
 <result pre="oral tablet NCT04322682 6000 March 2020â€&quot;September 2020 Phase 3 Montreal" exact="Heart" post="Institute Darunavir Drug: darunavir and cobicistat NCT04252274 30 January"/>
 <result pre="self-isolation are important strategies to avoid the spread of COVID-19" exact="infection" post="as mentioned by the Centers for Disease Control and"/>
 <result pre="spread of COVID-19 infection as mentioned by the Centers for" exact="Disease" post="Control and Prevention (CDC). Many drugs listed in this"/>
 <result pre="virus is going to be challenging owing to the possible" exact="viral" post="genetic recombinations. Extensive research is still needed to safely"/>
 <result pre="is the diagnostic questionPostgrad Med JColemanJJManaviKMarsonEJBotkaiAHSapeyE39239896202032522844 2Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J MedGuanWJNiZYHuYet al.17081720382202032109013 3A novel"/>
 <result pre="Engl J MedGuanWJNiZYHuYet al.17081720382202032109013 3A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J MedZhuNZhangDWangWet al.727733382202031978945 4Therapeutic options"/>
 <result pre="outbreakCurr BiolZhangTWuQZhangZ1346135130202032197085 8The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the statusMil"/>
 <result pre="the statusMil Med ResGuoYRCaoQDHongZSet al.117202032169119 9The pivotal link between ACE2" exact="deficiency" post="and SARS-CoV-2 infectionEur J Intern MedVerdecchiaPCavalliniCSpanevelloAAngeliF142076202032336612 10Functional assessment of"/>
 <result pre="BioRender.com920202020https://app.biorender.com/biorender-templates 12Review of emerging pharmacotherapy for the treatment of coronavirus" exact="disease" post="2019PharmacotherapyBarlowALandolfKMBarlowBYeungSYHeavnerJClaassenCWHeavnerM41643740202032259313 13Learning from the past: possible urgent prevention and"/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019â€�nCoVChemBioChemMorseJSLalondeTXuSLiuWR73073821202032022370 14Coronavirus replication cycle by"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019â€�nCoVChemBioChemMorseJSLalondeTXuSLiuWR73073821202032022370 14Coronavirus replication cycle by BioRender.com920202020https://app.biorender.com/biorender-templates"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019â€�nCoVChemBioChemMorseJSLalondeTXuSLiuWR73073821202032022370 14Coronavirus replication cycle by BioRender.com920202020https://app.biorender.com/biorender-templates 15Coronavirus"/>
 <result pre="infections caused by 2019â€�nCoVChemBioChemMorseJSLalondeTXuSLiuWR73073821202032022370 14Coronavirus replication cycle by BioRender.com920202020https://app.biorender.com/biorender-templates 15Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBioAgostiniMLAndresELSimsACet al.01892018 16VekluryÂ® (remdesivir) official"/>
 <result pre="practice - evidenceâ€�based approach from the Writing Committee of the" exact="American" post="Society for Apheresis: the Eighth Special IssueJ Clin ApherPadmanabhanAConnellyâ€�SmithLAquiNet"/>
 <result pre="of SARS-CoV-2 infection-a review of immune changes in patients with" exact="viral" post="pneumoniaEmerg Microbes InfectLinLLuLCaoWLiT7277329202032196410 23FDA: recommendations for investigational COVID-19 convalescent"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw"/>
 <result pre="Netw OpenBorbaMGSValFFASampaioVSet al.032020 31First evaluations of LPV/RTV (Kaletra) efficacy on" exact="HIV-positive" post="patients treated with multiple drugs. (Article in Italian)Infez MedSabbataniSLegnaniGFulgaroC1824112003https://www.infezmed.it/index.php/article?Anno=2003&amp;amp;numero=1&amp;amp;ArticoloDaVisualizzare=Vol_11_1_2003_1812719666"/>
 <result pre="syndromeOncologistLeRQLiLYuanWet al.94394723201829622697 37Can we use interleukin-6 (IL-6) blockade for coronavirus" exact="disease" post="2019 (COVID-19)-induced cytokine release syndrome (CRS)?J AutoimmunLiuBLiMZhouZGuanXXiangY102452111202032291137 38Coronavirus disease"/>
 <result pre="interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release" exact="syndrome" post="(CRS)?J AutoimmunLiuBLiMZhouZGuanXXiangY102452111202032291137 38Coronavirus disease 2019 (COVID-19): a clinical updateFront"/>
 <result pre="coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?J AutoimmunLiuBLiMZhouZGuanXXiangY102452111202032291137 38Coronavirus" exact="disease" post="2019 (COVID-19): a clinical updateFront MedZhouMZhangXQuJ12613514202032240462 39Effective treatment of"/>
 <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the perspectives of clinical immunologists from ChinaClin"/>
 <result pre="inhibitors, repurposing against COVID-19Life SciElfikyAA117477248202032119961 46Outcomes in patients with COVID-19" exact="infection" post="taking ACEI/ARBCurr Cardiol RepRico-MesaJSWhiteAAndersonAS3122202032291526 47Home page: ClinicalTrials.gov920202020https://clinicaltrials.gov/ 48Mesenchymal stem"/>
</results>
